Literature DB >> 17076535

Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.

Robert C Hawley1, Milena Cankovic, Richard J Zarbo.   

Abstract

Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency. Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states. However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported. We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma. The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion. Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17076535     DOI: 10.5858/2006-130-1707-ATLWSE

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature.

Authors:  Yaya Wang; Bailu Xie; Yu Chen; Zhenqian Huang; Huo Tan
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

3.  A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma.

Authors:  Mi-Hye Lee; Ik-Jun Moon; Woo-Jin Lee; Chong-Hyun Won; Sung-Eun Chang; Jee-Ho Choi; Mi-Woo Lee
Journal:  Ann Dermatol       Date:  2016-11-23       Impact factor: 1.444

4.  Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma.

Authors:  Yi Zhou; Marc K Rosenblum; Ahmet Dogan; Achim A Jungbluth; April Chiu
Journal:  J Hematop       Date:  2015-03-18       Impact factor: 0.196

5.  Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

Authors:  Katja C Weisel; Eckhart Weidmann; Ioannis Anagnostopoulos; Lothar Kanz; Antonio Pezzutto; Marion Subklewe
Journal:  Int J Hematol       Date:  2008-10-07       Impact factor: 2.490

6.  Epstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment.

Authors:  Chaoyu Wang; Yi Gong; Qingming Jiang; Xiping Liang; Rui Chen
Journal:  Clin Case Rep       Date:  2021-05-05

Review 7.  Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.

Authors:  Qing-Xu Yang; Xiao-Juan Pei; Xiao-Ying Tian; Yang Li; Zhi Li
Journal:  Diagn Pathol       Date:  2012-01-19       Impact factor: 2.644

8.  Identification of cell-type-specific mutations in nodal T-cell lymphomas.

Authors:  T B Nguyen; M Sakata-Yanagimoto; Y Asabe; D Matsubara; J Kano; K Yoshida; Y Shiraishi; K Chiba; H Tanaka; S Miyano; K Izutsu; N Nakamura; K Takeuchi; H Miyoshi; K Ohshima; T Minowa; S Ogawa; M Noguchi; S Chiba
Journal:  Blood Cancer J       Date:  2017-01-06       Impact factor: 11.037

9.  Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma.

Authors:  Taegeun Lee; Borae G Park; Eunkyoung You; Young Uk Cho; Seongsoo Jang; Sun Mi Lee; Cheolwon Suh; Chan Jeoung Park
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.